Efficacy of Blue light in mild and moderate facial acne vulgaris

Muhammad Faizan Alam, Syed Kamran ul Hassan, Sehrish Ashraf


Objective To determine the efficacy of blue light treatment in patients with mild and moderate facial acne vulgaris.


Methodology This quasi-experimental study was performed at Department of Dermatology, Services Hospital, Lahore from 31st January 2015 to 30th July 2015. Total 105 patients were included in the study by non-probability consecutive sampling. The patients undergone 16 sessions of blue light for 15 minutes each, twice a week for 8 weeks. Global Acne Score (GAS) was calculated at the start of the treatment and at 8 weeks. Mean reduction in GAS was measured. The statistical analysis was performed using SPSS version 16.


Results 91(87%) patients were between 15-30 years of age while 14 (13%) were between 31-45 years of age with mean age of 22.90±5.97 years.  28 (26.7%) were male and 77 (73.3%) were females. Acne was mild in 50 (47.6 %) patients and moderate in 55 (52.4%). Pretreatment mean global acne score was 18.9905±6.24884 and posttreatment mean global acne score was 15.1143±5.1143. Mean reduction in global acne score after 08 weeks was 3.87619±3.33021 (p <0.0038).


Conclusion Blue light is an effective monotherapy in the treatment of mild and moderate facial acne vulgaris in our population.




Acne Vulgaris, Blue light, Global acne score ( GAS)

Full Text:



James WD, Berger TG, Elston DM, editors. Andrew’s Disease of Skin. Clinical Dermatology, 11th edn. Philadelphia: Saunders Elsevier; 2011. P. 228-9.

Layton AM. Disorders of sebaceous glands. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology, 8th edn. Oxford: Wiley-Blackwell; 2010. P. 42.17-24.

Dawson LA, Dellavalle PR. Acne vulgaris, clinical review. BMJ. 2013;346:f2634.

Tan JK, Tang J, Fung K. Prevalence and severity of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008;7:551-6.

Halversen JA, Stern RS, Dalgard F, Thorsen M, Bjertness E, Lien L. Suicidal Ideation, mental health problems, and social impairment are increased in adolescents with acne: A population-based study. J Invest Dermatol. 2011;131:363-70.

Simonart T. Newer approaches to the treatment of acne vulgaris. Am J Clin Dermatol. 2012;13:357-64.

Whitney KM, Ditre CM. Management strategies in acne vulgaris. Clin Cosmet Invest Dermatol. 2012;4:41-53.

Bowe W, Kober M. Therapeutic update: acne. J Drugs Dermatol. 2014;13:235-8.

Dai T, Gupta A, Murray CK, Vrahas MS, Tegos GP, Hamblin MR. Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond? Drug Resist Updat. 2012;15:223-36.

Rai R, Natarajan K. Laser and light based treatments in acne vulgaris. Indian J Dermotol Leprol. 2013;79:300-9.

Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168:474-85.

Al Mutairi N, Marchland Y, Nour-Eldin O, Sultan O. Isotretinoin in acne vulgaris; a prospective analysis of 160 cases from Kuwait. J Drugs Dermatol. 2005;27:34-40.

Adulwahab M, Rehman MH, Monamie NS, Jamalludin M, Khondker L, Afroz W. Isotretinoin versus weekly pulse dose azithromycin in the treatment of acne-a comparative study. J Pak Assoc Dermatol. 2008;18:9-14.

Faghihi G. Vali A, Asilian A, Radan RM, Esteki H, Elahidoost M. Comparative efficacy of filtered blue light (emitted from sunlight) and topical erythromycin solution in acne treatment: a randomized controlled clinical trial. J Pak Assoc Dermatol. 2011;21:179-84.


  • There are currently no refbacks.

ISSN: 1560-9014